Novotech is a company that does research. They have announced that Dr. Anand Tharmaratnam is now the Chief Executive Officer. This was a planned change to help the company grow more around the world.
Dr. Tharmaratnam is now in charge of Novotech as the Chairman and Chief Executive Officer. He started doing this job on 1 January 2026. Novotech has a main office in Singapore and Dr. Tharmaratnam will work from there. This shows that Singapore is an important place for clinical research and, for companies that work with living things to grow.
Dr. Tharmaratnam has thirty years of experience in the contract research and life sciences sector. He is now doing things in his new role. Before he became the CEO of Novotech he was the Chairman of the Board. He started doing that job in 2021. As Chairman of the Board Dr. Tharmaratnam was an important leader. He helped Novotech make plans and get bigger. The company was able to do things for its clients who are in the biotech and pharmaceutical businesses all around the world. Dr. Tharmaratnam and the people, at Novotech worked hard to make this happen. Before he worked at Novotech he was at Quintiles. Then IQVIA for twenty three years. He was with these companies that run clinical trials for other people. At Quintiles and IQVIA he was on the team that made decisions for ten years. He was in charge of Asia and Japan for them. This experience gave him a lot of knowledge about how clinical trials work in countries and what rules he had to follow. He really understood the trial operations and regulatory environments, around the world especially at Novotech and these other companies, Quintiles and IQVIA.
The change in leadership at Novotech happens after they made a plan for who would be in charge. This plan started when Dr. John Moller, the CEO of Novotech said he would leave his job at the end of 2025. He was the CEO of Novotech for nine years. This change is happening at the time that Novotech is growing really fast. The company got a lot of money from investors in March 2025. Investors, like GIC and Temasek and also TPG which has been helping Novotech for a time gave them a lot of money. The money that was added to Novotech has made Novotechs financial situation better. This has helped Novotech to improve the services it provides to people. It has also helped Novotech to expand to more places. Novotech can now deliver its services in a way and Novotech has a bigger geographic footprint. This is good, for Novotech.
Dr. Tharmaratnam made some statements for the first time as the CEO. He said that Novotech will keep doing a job with science and coming up with new ideas. Dr. Tharmaratnam also said that Novotech will always put its clients first.
He talked about how important it’s for Novotech to be a top biotech clinical research partner. This is especially true in the Asia-Pacific region, North America and Europe. Novotech wants to be the best, in these places. This is a part of what Novotech is trying to do. Novotech is going to do some things under his leadership. They plan to get even bigger, around the world. Novotech will put money into technologies and systems that use data to make good decisions. This will help Novotech get better at science. Novotech needs to get better at science to help the companies that make medicines. These companies have complicated programs that involve many countries. Novotech wants to be able to support these programs for their clients.
Novotech does a lot of things to help with trials. This includes managing the trials dealing with regulations finding patients and looking at data. This makes Novotech a great partner for companies that are working on treatments. Novotech is lucky to have Dr. Tharmaratnam in charge. He will help the company keep doing what it is good at. The company will keep being a player in the field because it is always changing and companies need to find ways to develop drugs quickly. Novotech will keep being a choice, for companies that need help with this.
Context on Novotech:
Novotech is recognised as a globally integrated clinical research organisation serving biotech and pharmaceutical companies with services across clinical operations, scientific advisory, and regulatory compliance. It has a wide international footprint with offices in key markets and a track record of facilitating complex clinical programs across diverse therapeutic areas.
